Avalo Therapeutics AVTX
NASDAQ AVTX
$8.51 +1.35 (+18.85%)
At close: Nov 11, 2026 · 4:00 PM EST

Avalo Therapeutics (AVTX) Asset Writedowns and Impairment (2018)

Updated

Avalo Therapeutics (AVTX) recorded Asset Writedowns and Impairment of $3.91 million in FY2023.

Analysis

Avalo Therapeutics (AVTX) Asset Writedowns and Impairment (2018) Analysis & Trends

  • Annual Asset Writedowns and Impairment has a five-year compound annual growth rate of 15.5% (FY2018 to FY2023).
  • The FY2023 figure is the lowest annual Asset Writedowns and Impairment since FY2019.
  • Per Business Quant data, AVTX's Asset Writedowns and Impairment was $1.45 million in FY2019 (-23.7%).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Avalo Therapeutics 386.09 Mn -587.48 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2018 38,438.00
Sep 30, 2018 159,687.00
Jun 30, 2018 1.70 Mn
API Access

Avalo Therapeutics Asset Writedowns and Impairment API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=asset-writedowns-and-impairment&ticker=AVTX&period=max&api_key=YOUR_API_KEY